Skip to main content
. 2009 Sep;4(9):1465–1476. doi: 10.2215/CJN.06141108

Table 4.

Overall summary of serum Ca, serum P, and Ca × P values at selected visitsa

Time Period Ca (mg/dl)
P (mg/dl)
Ca×P (mg2/dl2)
Original Cinacalcet Original Placebo Original Cinacalcet Original Placebo Original Cinacalcet Original Placebo
Baseline (lead-in study)
    Mean (SE) 9.83 (0.04) 9.88 (0.05) 6.23 (0.09) 6.11 (0.09) 61.01 (0.90) 60.27 (0.94)
    Median (Q1, Q3) 9.80 9.83 6.00 6.12 58.99 60.18
(9.27, 10.27) (9.24, 10.49) (5.10, 7.27) (5.00, 7.03) (48.78, 71.46) (50.72, 69.91)
    [n] [334] [255] [334] [255] [333] [255]
Week 34 (end of titration)b
    Mean (SE) 9.17 (0.05) 9.24 (0.07) 5.72 (0.11) 5.61 (0.11) 52.44 (1.03) 51.73 (1.08)
    Median (Q1, Q3) 9.20 9.20 5.60 5.50 51.66 49.00
(8.50, 9.80) (8.45, 9.95) (4.45, 6.90) (4.40, 6.70) (39.72, 62.64) (39.33, 62.89)
    [n] [318] [243] [312] [240] [312] [240]
Week 58 (end of maintenance)c
    Mean (SE) 9.26 (0.06) 9.06 (0.07) 5.70 (0.11) 5.58 (0.13) 52.70 (1.00) 50.37 (1.19)
    Median (Q1, Q3) 9.20 9.10 5.50 5.50 52.14 49.50
(8.70, 9.80) (8.43, 9.70) (4.40, 6.70) (4.20, 6.60) (40.04, 63.19) (38.54, 58.00)
    [n] [273] [192] [269] [189] [269] [189]
End follow-up phase (week 180)
    Mean (SE) 9.43 (0.32) 9.58 (0.28) 5.99 (0.42) 5.21 (0.76) 56.02 (4.06) 52.72 (8.01)
    Median (Q1, Q3) 9.75 9.65 5.90 4.20 54.02 44.25
(8.90, 10.20) (8.95, 10.20) (5.80, 6.90) (3.50, 7.20) (49.56, 61.95) (37.03, 69.60)
    [n] [10] [8] [9] [9] [9] [8]
a

Some scheduled visits were shifted up to a maximum of 2 wk to align with the closest week indicated in the table.

b

Week 34 corresponds to end-of-dose-titration phase for subjects whose lead-in study duration was 26 wk.

c

Week 58 corresponds to end of maintenance phase for subjects whose lead-in study duration was 26 wk.